title: Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization.
abstract: In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam's utilization was classified as appropriate based on Canadian IVIg guidelines.
authors.affiliation: St Michael's Hospital and the University of Toronto, 30 Bond St, Toronto, ON M5B 1W8 Canada.
authors.forename: Stephen D
authors.identifier: 0000-0002-6631-4438
authors.initials: SD
authors.lastname: Betschel
authors.affiliation: Head, Section of Allergy & Immunology, Department of Internal Medicine, University of Manitoba, Winnipeg Health Science Center, GC319 820 Sherbrook St, Winnipeg, MB R3A 1R9 Canada.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Warrington
authors.affiliation: St Paul's Hospital and the University of British Columbia, 1081 Burrard St, Vancouver, BC V6C 1Y6 Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Schellenberg
keywords: IVIg; Indication; Octagam®